Neuphoria Therapeutics Inc.

Neuphoria Therapeutics Inc. is a clinical-stage biotechnology company focused on fulfilling public-company obligations, preserving capital, and executing a proposed merger transaction. The company centers its research activities on an alpha7 nicotinic acetylcholine receptor negative allosteric modulator portfolio. Its primary proprietary asset, BNC210, is maintained in clinical readiness for post-traumatic stress disorder following the discontinuation of its social anxiety disorder program. Neuphoria also manages economic interests in partnered programs, including allosteric modulators partnered with Merck, a KAT6 oncology program licensed to Pfizer, and a CAR-T therapeutic developed by Carina Biotech. Because its assets are clinical-stage therapies, Neuphoria serves no commercial customers.

Neuphoria terminated its facility leases and retains only one full-time employee, managing ongoing administrative and ordinary course operations through external consultants. Its completed clinical trials have taken place across the United States, Australia, the United Kingdom, and France. Neuphoria is a Delaware corporation.

Summary of the business section of Neuphoria Therapeutics's latest annual report, written by StockData.

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

“As of June 30, 2025, we had a total of seven full-time employees, one part-time employee, and sixteen part-time consultants.”